SALT LAKE CITY, Oct. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Steve Stone, Ph.D., Vice President of Cancer Genomics, is scheduled to present data on PROLARIS™, Myriad’s prognostic medicine product for prostate cancer, at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer to be held from October 18-20, 2010, at the Westin Diplomat Hotel in Hollywood, Florida.
